Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Rena Xian"'
Autor:
Paola Ghanem, Maria Fatteh, David Olayinka Kamson, Archana Balan, Michael Chang, Jessica Tao, Jaishri Blakeley, The Johns Hopkins Molecular Tumor Board Investigators, Jenna Canzoniero, Stuart A. Grossman, Kristen Marrone, Karisa C. Schreck, Valsamo Anagnostou, Christine Pratilas, Taxiarchis Botsis, Rena Xian, Chris Gocke, Tseh Ming-Lin, Eitan Halper-Stromberg, Ying Zou, Kent Hardart, Jonathan Spiker, Kory Kreimeyer, Ting He, Katie Fiallos, Dana Petry, Kala Visvanathan, Antonio Wolff, Cesar Santa-Maria, Raquel Nunez, Christian Meyer, John Laterra, Vered Stearns, Karen Smith, Deborah Armstrong, Rachel Karchin, Katerina Karaindrou, Lily Zandi, Marta Majcherska, Faith Too, Monique Makell, Jennifer Lehman, Timsy Wanchoo, Jaime Wehr, Michael Conroy, Selina Shiqing Teh.
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundDespite the putatively targetable genomic landscape of high-grade gliomas, the long-term survival benefit of genomically-tailored targeted therapies remains discouraging.MethodsUsing glioblastoma (GBM) as a representative example of high-gr
Externí odkaz:
https://doaj.org/article/5bcfd0838b504f0dae83f9e83188528c
Autor:
Erika F. Rodriguez, Federico De Marchi, Parvez M. Lokhandwala, Deborah Belchis, Rena Xian, Christopher D. Gocke, James R. Eshleman, Peter Illei, Ming‐Tseh Li
Publikováno v:
Cancer Medicine, Vol 9, Iss 12, Pp 4386-4394 (2020)
Abstract Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2‐mutated non–small cell
Externí odkaz:
https://doaj.org/article/d4066f83fadc406b860f4b17fa765af8
Autor:
Gang Zheng, Christopher D. Gocke, Li Hui Tseng, Erika F. Rodriguez, Ming-Tseh Lin, Rena Xian, Ying Zou, James R. Eshleman, Vamsi Parini
Publikováno v:
American Journal of Clinical Pathology. 157:244-251
Objectives To demonstrate clinicopathologic features and evaluate the clonality of double PIK3CA alterations in colorectal cancers (CRCs). Methods Clonality was examined in 13 CRCs with double PIK3CA alterations (1.7% of CRCs or 9.6% of PIK3CA-mutate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3704edb858c3ea71a4467710840f9791
https://doi.org/10.1093/ajcp/aqab119
https://doi.org/10.1093/ajcp/aqab119
Autor:
Vamsi Parini, Liam Chen, Jialing Huang, Aparna Pallavajjala, Rena Xian, Ming Tseh Lin, Christopher D. Gocke, Li Hui Tseng, James R. Eshleman, Erika F. Rodriguez, Parvez M. Lokhandwala
Publikováno v:
American Journal of Clinical Pathology. 156:777-786
Objectives To elucidate clinicopathologic and molecular characteristics of IDH1 and IDH2 (IDH1/2) mutations in colorectal cancers (CRCs). Methods We evaluated IDH1/2 mutations in 1,623 CRCs using a next-generation sequencing assay. Results IDH1/2 mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7fcd31b3a0b531a4fd49d6ed2c9131
https://doi.org/10.1093/ajcp/aqab023
https://doi.org/10.1093/ajcp/aqab023
Autor:
Rena Xian, Federico De Marchi, Peter B. Illei, Deborah A. Belchis, Jialing Haung, Christopher D. Gocke, Erika F. Rodriguez, James R. Eshleman, Li Hui Tseng, Ming Tseh Lin
Publikováno v:
Molecular Diagnosis & Therapy. 24:461-472
Differentiation between intrapulmonary metastasis (IPM) and multiple primary lung cancers (MPLC) in patients with synchronous or metachronous lung tumor nodules is critical but challenging. We proposed an algorithm to evaluate clonal origin based on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abd7f4b4b511c3a20bc5ca09c12f5749
https://doi.org/10.1007/s40291-020-00471-w
https://doi.org/10.1007/s40291-020-00471-w
Autor:
Brigitte M. Ronnett, James R. Eshleman, Rena Xian, Deyin Xing, Denise A.S. Batista, Jennifer Bynum, Gang Zheng
Publikováno v:
The Journal of Molecular Diagnostics. 22:90-100
DNA genotyping studies have established that most partial hydatidiform moles (PHMs) are diandric dispermic triploid conceptions. Rare triandric tetraploid PHMs have been described, but genotyping cannot determine the manner in which three paternal ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1926894515f42777612a9f6532c17da0
https://doi.org/10.1016/j.jmoldx.2019.09.006
https://doi.org/10.1016/j.jmoldx.2019.09.006
Autor:
BOTSIS, Taxiarchis, SPIKER, Jonathan, KREIMEYER, Kory, FATTEH, Maria, WEHR, Jamie, NAJJAR, Mimi, TAO, Jessica, Rena XIAN, IMAMOVIC, Nicole L, PINDZOLA, Ander, DOBS, Adrian, CANZONIERO, Jenna, ANAGNOSTOU, Valsamo
Publikováno v:
Studies in Health Technology & Informatics; 2024, Vol. 316, p1854-1855, 2p
Autor:
Julia A. Bridge, Alissa Keegan, Mark J. Routbort, Jason D. Merker, Joel T. Moncur, Rakesh Nagarajan, Paul G. Rothberg, Nathan D. Montgomery, Neal I. Lindeman, Patricia Vasalos, Rena Xian, Annette S. Kim, Thomas A. Long
Publikováno v:
Archives of pathologylaboratory medicine.
Context.— As laboratories increasingly turn from single-analyte testing in hematologic malignancies to next-generation sequencing–based panel testing, there is a corresponding need for proficiency testing to ensure adequate performance of these n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::455eb519d30496208276ce74c0f37a91
https://pubmed.ncbi.nlm.nih.gov/31986076
https://pubmed.ncbi.nlm.nih.gov/31986076
Autor:
Erika F. Rodriguez, Rena Xian, Parvez M. Lokhandwala, James R. Eshleman, Deborah A. Belchis, Federico De Marchi, Ming Tseh Li, Christopher D. Gocke, Peter B. Illei
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 12, Pp 4386-4394 (2020)
Cancer Medicine, Vol 9, Iss 12, Pp 4386-4394 (2020)
Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2‐mutated non–small cell lung can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5f1286936347bf7efd0b83b9cf54008
https://pubmed.ncbi.nlm.nih.gov/32333643
https://pubmed.ncbi.nlm.nih.gov/32333643
Autor:
Gabriel Ghiaur, Christopher S. Hourigan, Rena Xian, Laura W. Dillon, Pradeep K. Dagur, Chidera Nosiri, Philip McCoy, Meghali Goswami, Gege Gui
Publikováno v:
Blood. 138:1289-1289
Background: Chromosome 7 (chr7) abnormalities are commonly seen in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome and are associated with poor prognosis. Flow cytometry (FCM) is typically used clinically to quantify residual m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc29026eb432f6cf7073dc316e2faf69
https://doi.org/10.1182/blood-2021-152669
https://doi.org/10.1182/blood-2021-152669